ProFunds Biotechnology UltraSector Inv (BIPIX)
When purchasing a mutual fund, I would pick BIPIX. According to Morningstar.com, BIPIX is the top mutual fund in the health category. It's high numbers make it a mutual fund that I will look after.
Currently BIPIX is down 0.28%. However after looking at it's holdings, I have seen plenty of information that reenforce that fact that this is worth purchasing. According to the Equity Holdings chart, the earnings for BIPIX are at 20.58 while the category average for earnings is 17.12. The earnings growth for BIPIX over three years was 26.29%. The category average was only 8.92%. BIPIX also surpassed the category average in sales and cashflow.
Morningstar gave BIPIX a return rating of 5.00. It's best return over one year was 65.82% which was for 2012. It's worst return over one year was in 2002 of 53.68%. Since 2009, the returns have been increasing annually. In every time period, BIPIX is ranked the best in total returns. This includes over a 5 year span all the way down to a 1 month span.
The fund is currently worth $154.66 and is down 0.28%. It's previous closing was at $155.09. Looking at a chart of BIPIX over the last 3-6 months, the fund has not been fluctuating dramatically and is steadily increasing over time.
This mutual fund is managed by Hratch Najarian. He work as a portfolio analyst for ProFund Advisors since 2004. He is well experienced in this area and knows how to manage this well. Najarian has been the lead manager since September 2011. This earnings growth dramatically increasing in 2012, which means that Najarian must have led this fund into the right direction.
After looking at the fund's holdings, performance, quotes, reports and profile, I believe that it is worth purchasing BIPIX. This fund has been doing exceedingly well recently and it is worth investing into. Healthcare is an important part of the economy and most the top ten holdings of BIPIX are doing well for the fund to keep growing.
| Top 10 Holdings (51.74% of Total Assets) |
|---|
|
-Alexey Shamray






0 comments:
Post a Comment